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A B S T R A C T
Glycogen disease type III (GSDIII), a rare incurable autosomal recessive disorder due to glycogen debranching
enzyme deﬁciency, presents with liver, heart and skeletal muscle impairment, hepatomegaly and ketotic hy-
poglycemia. Muscle weakness usually worsens to ﬁxed myopathy and cardiac involvement may present in about
half of the patients during disease. Management relies on careful follow-up of symptoms and diet. No common
agreement was reached on sugar restriction and treatment in adulthood.
We administered two dietary regimens diﬀering in their protein and carbohydrate content, high-protein
(HPD) and high-protein/glucose-free (GFD), to our mouse model of GSDIII, starting at one month of age. Mice
were monitored, either by histological, biochemical and molecular analysis and motor functional tests, until
10 months of age.
GFD ameliorated muscle performance up to 10months of age, while HPD showed little improvement only in
young mice. In GFD mice, a decreased muscle glycogen content and ﬁber vacuolization was observed, even in
aged animals indicating a protective role of proteins against skeletal muscle degeneration, at least in some
districts. Hepatomegaly was reduced by about 20%. Moreover, the long-term administration of GFD did not
worsen serum parameters even after eight months of high-protein diet. A decreased phosphofructokinase and
pyruvate kinase activities and an increased expression of Krebs cycle and gluconeogenesis genes were seen in the
liver of GFD fed mice.
Our data show that the concurrent use of proteins and a strictly controlled glucose supply could reduce
muscle wasting, and indicate a better metabolic control in mice with a glucose-free/high-protein diet.
1. Introduction
Glycogen storage disease type III (GSDIII; OMIM #232400) is a rare
autosomal recessive disease [1,2] caused by deﬁciency of glycogen
debranching enzyme, one of the two enzymes responsible for glyco-
genolysis. Hepatomegaly, ketotic hypoglycemia, hyperlipidemia, ele-
vated transaminases and failure to thrive are the usual presenting
symptoms in the ﬁrst year of life in GSDIIIa (the most common subtype)
[1–3]. Hepatic symptoms usually improve and tend to resolve in ado-
lescence although liver ﬁbrosis and cirrhosis may develop [4,5].
Cardiac involvement, such as left ventricular wall thickness and mass
increase, occurs in about half of the patients, but generally is stationary
[3,6]. In young adults, myopathy initially presents mostly as exercise
intolerance, with involvement of both proximal and distal muscle and
elevated CK levels. A ﬁxed myopathy with proximo-distal involvement
of variable severity occurs in the following decades, eventually leading
to loss of independent walking. Muscle weakness is often described also
in young patients revealing that myopathy may occur earlier than
usually reported [2].
To date, there is no cure for GSDIII and the current
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recommendations for management rely on follow-up of symptoms and
dietary treatment to prevent hypoglycemia and maintain a constant
glycaemia. Particularly, in infancy and childhood fasting hypoglycemia
is less tolerated due to the age-dependent physiology. Euglycemia is
crucial in GSDIII patients but it is not enough to prevent long-term
complications such as myopathy and cardiomyopathy [7]. There is not
a common agreement about sugar restriction: some authors do not
suggest any sugar restriction [1], some others suggest avoiding simple
sugars like fructose and lactose in favor of complex carbohydrates [2].
Moreover, carbohydrate overload should be avoided as it may increase
glycogen storage, induce obesity and also insulin resistance [2]. An-
other emerging challenge is dietary treatment in adulthood.
A number of case reports focused on the improvement of myopathy
and/or cardiomyopathy in adults and children that switched their diet
in favor of high-protein diet [8–11] or high-fat/ketogenic diet [12–14].
Several beneﬁts come from by using high-protein diet in the treatment
of GSDIII: i) the metabolic pathway of gluconeogenesis is not damaged
and proteins can be used as source to produce glucose; ii) the increase
of dietary protein and the reduction of dietary carbohydrate may de-
crease glycogen storage in both liver and skeletal muscle; iii) increased
protein intake may reduce muscle proteolysis both by increasing the
availability of exogenous proteins for energy cell requirements and by
enhancing muscle protein synthesis for the maintenance of muscle
plasticity [2]. The administration of a high-protein diet in the man-
agement of GSDIII has its roots in the Sixties when Fernandes and van
de Kamer observed that proteins induce a gradual and prolonged in-
crease in blood glucose [15].
Recently, we developed a knock-out mouse model (GSDIII mouse
model) that reproduces the major features of GSDIII like hepatomegaly,
progressive glycogen storage in skeletal muscle and liver, and muscle
impairment [16]. We administered to GSDIII mice two types of high-
protein diet diﬀering in protein and carbohydrate content. Mice fed
with glucose-free/low-carbohydrate diet (GFD) showed signiﬁcant im-
provement of muscle performance, decreased glycogen accumulation
and reduction of hepatomegaly.
2. Material and methods
2.1. Animals and experimental protocols
All studies were approved by the Experimentation Committee
(OPBA) of the University of Milan and the Italian Ministry of Health
(Authorization number: 1169/2016-PR) and were performed in ac-
cordance with Italian guidelines for the use of laboratory animals. Mice
were maintained on a 12:12 h light-dark cycle in a temperature- and
humidity-controlled environment, and were allowed to free access to
standard (SD) or special diets (chow) and water.
The GSDIII mouse model was previously described [16]. Both
GSDIII and WT mice were fed with special diets starting from weaning
at 1month of age. High-protein (HPD; 49 kJ% protein, 31 kJ% carbo-
hydrates, 20 kJ% fat) and glucose-free/low-carbohydrate (GFD; 66 kJ%
protein, 2 kJ% carbohydrates, 32 kJ% fat) diets were from ssniﬀ ®
(ssniﬀ Spezialdiäten GmbH, Soest, Germany). For detailed diet com-
positions see Table 1.
A motorized treadmill (Panlab LE8708; Panlab Harvard Apparatus,
Spain) was used to assess muscle performance. Before testing, mice
were trained for two consecutive days on a 5° incline for 15min starting
at a speed of 5 cm/s and increasing the velocity of 5 cm/s every 5min.
The treadmill is supplied with an electriﬁed grid that administer a mild
shock (0.2 mA) to provide motivation. The exercise test was adminis-
tered after a 5min of warm up at a speed of 10 cm/s. The mice were
tested at 30 cm/s for 5min on a 5° incline. The test was interrupted
after 5min or when the mouse could no longer keep pace with the belt.
2.2. Serum analysis and biochemistry
Blood glucose was measured using test strips in a FreeStyle Optium
H system (Abbott Diabetes Care). Blood samples were collected from
tail vein.
For serum testing and biochemistry analysis, mice were anesthe-
tized and blood was sampled by puncture of vena cava in the sub-he-
patic tract. The procedure was followed by euthanasia. Serum was sent
to Charles River Laboratories for cholesterol, triglycerides, ALT, AST,
ALP, creatine kinases (CKs), blood urea nitrogen (BUN) and creatinine
determinations.
Glycogen content was determined as previously described [16,17].
The activities of glycolytic enzymes and of enzymes of each re-
spiratory chain complex were measured in tissue homogenates as pre-
viously described [18,19]. The activity of each complex was normalized
to that of citrate synthase.
2.3. Histological analysis
For light microscopy studies, fresh organs and tissues were pro-
cessed according to standard methods [20]. Routine stains with and
without prior diastase digestion were performed with hematoxylin and
eosin and periodic acid–Schiﬀ (PAS).
2.4. Glucose and glycogen metabolism expression proﬁle
We evaluated expression proﬁling of 84 genes involved in both
glucose and glycogen metabolism using the Mouse Glucose Metabolism
RT2 Proﬁler™ PCR Array (PAMM-006Z; SABiosciences, QIAGEN). Liver
and skeletal muscle (vastus) tissues from 2month-old mice were ana-
lyzed for WT, SD-KO and GFD-KO (n= 4). Equal amounts of total RNA
(0.5 μg for liver and 0.8 μg for vastus) were reverse transcribed using
the RT2 First Strand Kit (QIAGEN). Real-Time qPCR was performed in a
7500 Real Time PCR System (Applied Biosystems). The analysis of ex-
pression proﬁling was performed using the ΔΔCT method using the
online free software available at the PCR Array Data Analysis Web
portal (www.SABiosciences.com./pcrarraydataanalysis.php). Raw data
were normalized to the housekeeping genes included in the array.
Diﬀerentially expressed genes were identiﬁed using a 2-tailed t-test and
changes in gene expression were presented as fold change increase or
decrease (P value<0.05).
2.5. Statistical analysis
The survival time was calculated using the Kaplan–Meier log rank
test. Experimental groups were compared using Student's t-test and a P
value< 0.05 was considered statistically signiﬁcant. Error bars re-
present standard deviation.
Table 1
Composition of the diets administered in this study.
Nutrients Standard diet
(SD)
High protein
diet (HPD)
Glucose free diet
(GFD)
%
Crude protein 19.1 45.9 53.4
Crude fat 4.8 8.3 11.4
Crude ﬁber 3.8 5.0 20.3
Starch 35.4 9.6 0.1
Dextrin n.a. 6.9 –
Sugar (sucrose,
glucose)
4.6 11.0 < 0.1
Others 32.3 13.3 14.7
Total 100 100 100
n.a. not available.
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3. Results
To study the short-term and long-term eﬀects of diﬀerent protein
and carbohydrate loads, GSDIII mice were administered with a high-
protein diet (HPD; 45.9% protein) and a second diet with a higher
protein content (53.4% protein) and a glucose content< 0.1% of total
components (GFD), starting from one month of age. We previously
assessed that between 2 and 3months of age GDSIII mice are suscep-
tible to a decrease in muscle performance, evaluated as their ability to
run on a treadmill [16]. Therefore, we established two early time
points, at 2 and 3months of age, to study this critical moment for af-
fected mice, and a later time point, that includes animals between 8 and
12months of age. Mice fed with HPD or GFD did not show diﬀerences
in their growth curves respect to mice fed with standard diet (Suppl.
Fig. 1A). Also, we did not observe diﬀerences between treated or un-
treated male and female mice.
3.1. Eﬀects of HPD and GFD on liver and heart in GSDIII KO mice
Glycogen content in liver was not signiﬁcantly reduced neither by
HPD nor by GFD respect to untreated mice at any time point (Fig. 1A).
A signiﬁcant glycogen accumulation in hepatocytes was also apprai-
sable by histological analysis at all ages and independently of the type
of diet (Fig. 3B, D). The liver glycogen content lowered in WT mice fed
with GFD compared to WT mice fed with SD (Suppl. Fig. 4L).
Hepatomegaly, reported as percentage of liver weight on total body
weight, was not reduced in HPD-KO mice, indeed, the phenomenon
seemed enhanced at least in young ages (Fig. 1B). On the contrary,
hepatomegaly was signiﬁcantly reduced in GFD-treated mice at each
time point: the liver was, respectively, 24% (P < 0.01), 17%
(P < 0.05) and 22% (P < 0.001) smaller than in untreated mice
(Fig. 1B).
Biochemical assessment and PAS analysis of glycogen content in
cardiac muscle showed a modestly increased storage in 2-months old
HPD-mice (Figs. 1C; 3F, G, K, I). Also, in young HPD-KO mice, heart size
appeared to be increased compared to untreated mice at 2 (P < 0.05)
and 3 (P < 0.001) months of age (Fig. 1D). It is noteworthy that the
same occurred in HPD-WT mice compared to SD-WT mice (P < 0.05;
Suppl. Fig. 3G). Conversely, glucose-free diet had no inﬂuence on heart
size (Fig. 1D), though glycogen content in heart muscle was lower in 2-
month old treated mice (P < 0.01) than in SD-KO mice (Fig. 1C), as
indicated by PAS staining on heart (Fig. 3J–L).
3.2. Eﬀects of HPD and GFD on skeletal muscle in GSDIII KO mice
Biochemical assessment and PAS analysis of glycogen content in
Fig. 1. Short- and long-term eﬀects of HPD and GFD on liver and heart in GSDIII mice. A) Liver glycogen content in HPD- and GFD-KO mice did not show any
reduction respect to untreated mice. B) Liver weight expressed as percentage of whole body weight. HPD did not reduce hepatomegaly in treated mice. Instead,
hepatomegaly was signiﬁcantly reduced in mice fed with GFD at any time point showing long-term eﬀects of GFD. C) Glycogen content assessed in heart was not
reduced in HPD-treated mice at any time point. GFD-KO mice showed a signiﬁcant reduction of glycogen storage at 2 months of age respect to untreated mice. D)
Heart weight expressed as percentage of whole body weight. In HPD-KO mice of 2 and 3months of age heart appeared enlarged respect to SD-KO mice, whereas heart
size was not diﬀerent between GFD-KO and SD-KO mice.
Data are shown as mean ± standard deviation. *P < 0.05; **P < 0.01; ***P < 0.001 vs. SD-KO mice.
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gastrocnemius and vastus did not show diﬀerences between HPD-KO
and SD-KO mice at any time point (Figs. 2A, B; 3F, G, K, I). Histological
examination of tibialis and diaphragm from these mice evidenced no
major diﬀerences between the two groups, still showing many vacuoles
at any time point (Fig. 4). Conversely, less vacuolization and a better
architecture were observed in vastus and gastrocnemius (Fig. 4).
In GFD-KO mice, we observed a reduction of 44% (P < 0.01) of
glycogen content in the gastrocnemius at the last time point (Fig. 2A).
Interestingly, a reduction of glycogen storage of 24% (P < 0.05), 45%
(P < 0.05) and 53% (P < 0.01) could be clearly detected in vastus
(Fig. 2B). Furthermore, in GFD-WT mice glycogen content in the vastus
was almost 50% lower than in SD-WT mice, whereas glycogen content
in gastrocnemius did not change (Suppl. Fig. 5K; P < 0.05). The whole
data set indicated that GFD can limit glycogen accumulation in the
skeletal muscle, at least in some districts. Histological examination of
muscle tissue from GFD-KO mice aged 2, 3 and 9months, showed a
signiﬁcant reduction in the proportion of vacuolated ﬁbers, in the
vastus, gastrocnemius and diaphragm (Fig. 4). Improved morphological
features in vastus and gastrocnemius were strikingly evident even in
mice aged 9months. Conversely, the anterior tibialis remained severely
compromised, showing large vacuoles that replaced most of the sar-
coplasm (Fig. 4).
Muscle performance of treated mice was assessed each month using
a motorized treadmill (Fig. 2C). HPD-treated mice were able to run for
longer time than SD-KO mice at any time point up to 4months of age,
though data were statistically signiﬁcant only at 2months of age.
Nonetheless at 5months of age HPD-KO mice had the same disabilities
of untreated mice that let them run just for few seconds. Remarkably,
Fig. 2. Short- and long-term eﬀects of HPD and GFD on skeletal muscle in GSDIII mice. A, B) Glycogen content in gastrocnemius showed a signiﬁcant reduction in
GFD-KO mice at the last time point respect to untreated mice. When vastus was tested, GFD-KO mice showed a statistically signiﬁcant decrease of glycogen at each
time point. HPD did not show diﬀerences in glycogen content neither in gastrocnemius nor in vastus except a statically signiﬁcant increase at 3months of age. C) Run
test. After 10min of warm-up, mice were run on a treadmill with a 5° incline and a speed of 30 cm/s for a maximum of 5min (SD-WT n=5 (3M, 2F); SD-KO n=10
(6M, 4F), except 5-month-old SD-KO n=5 (3M, 2F); HPD-KO n=10 (7M, 3F); GFD-KO n=9 (3M, 6F), except 9 and 10month-old GFD-KO n=5 (5F)). HPD-KO
mice were able to run for longer time respect to mice fed with SD until 4 months of age. At 5months of age, both the treated and the untreated groups were able to
run just for few seconds. GFD-KO mice showed a substantial and signiﬁcant improvement of their motor abilities. They were able to run for longer time respect to
mice fed with SD and, even better, the muscle performance was maintained for a long period respect to SD-KO mice. At 10months of age, the muscle performance of
the treated group declined but was still higher than muscle performance of untreated 5month-old mice.
Data are shown as mean ± standard deviation. *P < 0.05; **P < 0.01; ***P < 0.001 vs. SD-KO mice.
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GFD-KO mice greatly improved their muscle performance running for
longer time respect to SD-KO: at 2months of age, GFD-treated mice run
269 ± 66 s vs. 154 ± 98 s of untreated mice (P < 0.05); at 3 months,
GFD-KO mice run 291 ± 23 s vs. 53 ± 32 s of untreated mice
(P < 0.001); at 4 months, the outcome was 204 ± 166 s vs. 35 ± 24 s
(P < 0.01), and at 5months, GFD-KO mice run 196 ± 125 s vs.
28 ± 20s of untreated mice (P < 0.01) (Fig. 2C). Muscle improve-
ment showed by GFD-treated mice allowed them to perform the run test
up to 10months of age, while mice fed with SD or HPD stopped at
5months. Though GSDIII mice responded very well to GFD, between 8
and 9months of age their muscle performance lowered and all the mice
of the test group leveled oﬀ.
3.3. Serum biochemistry in HPD-KO and GFD-KO mice
Both HPD- and SD-KO mice showed transaminase levels higher than
WT mice (Suppl. Fig. 2A, B), without signiﬁcant changes between the
treated and the untreated group. The GSDIII mouse model is char-
acterized by lower levels of blood glucose than WT mice in both the fed
and the fasted states [16]. HPD-KO mice still had low glycaemia com-
parable to untreated mice (Suppl. Fig. 2C). BUN and creatinine were
investigated to evaluate the impact of the high-protein load on kidneys
(Suppl. Fig. 2D, E). BUN was 72% (P < 0.01), 96% (P < 0.01) and
35% (P < 0.05) higher in treated mice at each time point, respectively.
An increase of BUN was also observed in WT mice fed with HPD due to
the considerable amount of protein intake (Suppl. Fig. 3D, E). Creati-
nine levels were similar between WT, untreated and HPD-KO mice (WT
0.19 ± 0.03mg/dL; SD-KO 0.20 ± 0.00mg/dL; HPD-KO
0.22 ± 0.04mg/dL; n=9).
Young GFD-KO mice showed cholesterol levels lower than untreated
and WT mice (2-month old GFD-KO mice P < 0.05), whereas trigly-
ceride levels were in the normal range (Suppl. Fig. 4A, B).
Transaminase and ALP levels were similar in both treated and untreated
group at any time point (Suppl. Fig. 4C–E), as well as glycaemia (Suppl.
Fig. 4F). BUN was higher in treated mice at any time point (+55%
(P < 0.01), +103% (P < 0.01) and+70% (P < 0.05), respectively)
(Suppl. Fig. 4G, H). Creatinine levels were lower in GFD-KO mice re-
spect to both untreated and WT mice (WT 0.19 ± 0.03mg/dL; SD-KO
0.15 ± 0.05mg/dL; GFD-KO 0.11 ± 0.03mg/dL; n=9). BUN also
increased in WT mice fed with GFD, due to the amount of protein in-
take, but in these mice the increase observed was lower than in GFD-KO
and of no statistical signiﬁcance (Suppl. Figs. 4G, H; 5G, H).
PAS staining of kidney did not show any changes in mice fed with
GFD or HPD respect SD-KO mice (Fig. 3M–P).
We next evaluated if GFD had eﬀects on the fasting state (Fig. 5).
After an overnight fasting, blood samples were collected from GFD-KO
mice and SD-KO. Interestingly, when fasted, the latter showed great
increase of ALT (SD-KO 114.2 ± 48.8 U/L vs. GFD-KO 22.8 ± 11.0 U/
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Fig. 3. PAS staining. Liver showed a considerable accumulation of glycogen in all the mice tested, independently of the diet (A-D). PAS staining showed an important
reduction in glycogen storage in muscular and cardiac tissues from GFD-KO mice compared to HPD- and SD-KO mice (E-H; J-L). Glycogen content in kidney from SD-
KO mice did not show any changes respect to WT mice (M-P). Analyzed tissues were from 3-month old mice. Liver (A-D) and heart (J-L): bar 25 μm. Skeletal muscle
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L, P < 0.05), AST (SD-KO 765.0 ± 261.7 U/L vs. GFD-KO
399.6 ± 278 U/L, P < 0.05), ALP (SD-KO 137.0 ± 33.8 U/L vs. GFD-
KO 83.2 ± 12.7 U/L, P < 0.05) and CKs (SD-KO 231.2 ± 191.6 U/L
vs. GFD-KO 54.2 ± 42.5 U/L) (Fig. 5C–F). GFD-KO mice when fasted
showed little increase of these values compared to unfasted GFD-KO
mice, and a stronger decrease of cholesterol (P < 0.05), triglycerides
and glucose (P < 0.001) than fasted SD-KO mice (Fig. 5A, B, G). BUN
increased in fasted SD-KO mice, while it decreased in fasted GFD-KO
mice (SD-KO 39.2 ± 2.1mg/dL vs. GFD-KO 32.0 ± 3.7mg/dL,
P < 0.01), likely due to both the stop of protein intake and the sparing
of muscle proteins as energy source which gained importance in a cri-
tical condition of lack of nutrients (Fig. 5H). The BUN/creatinine ratio
decreased too (Fig. 5I).
3.4. Survival
Since we previously observed that GSDIII mice have reduced sur-
vival compared to WT mice [16], we compared the life span of treated
and untreated mice (Suppl. Fig. 1B). Kaplan-Meier survival showed a
median survival time of 291.0 days (P < 0.01) for HPD-KO mice and a
median survival time of 331.5 days (P=0.44) for GFD-KO compared to
393.5 days for SD-KO mice.
3.5. Expression proﬁling of glucose and glycogen metabolism in untreated-
and GFD-KO mice
We studied the expression proﬁling of 84 genes involved in glucose
and glycogen metabolism in both liver and skeletal muscle to elucidate
the metabolic proﬁling of GSDIII mice and the potential changes in-
duced by GFD (Fig. 6). After entering the cell, glucose is addressed to
diﬀerent metabolic pathways according to cell requirements: i) cata-
bolism through glycolysis when energy is needed; ii) conversion in
pentose phosphates; iii) storage as glycogen when the cell does not need
more energy; iv) or release in the blood ﬂow when glycaemia decreases.
Liver and skeletal muscle (vastus) tissues were collected from the same
animals of 2months of age.
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Fig. 5. Metabolic outcomes of GFD in fasted
and unfasted mice. A, B) Cholesterol and
triglyceride evaluation showed a decrease of
cholesterol content in fasted GFD-KO mice,
whereas triglycerides were the same in both
groups and in both conditions. C-E) ALT,
AST and ALP showed a high increase in
fasted SD-KO mice, while fasted GFD-KO
mice showed only a slight increase in these
values respect to ad libitum fed mice. F) CK
levels dramatically increased in fasted SD-
KO mice. In fasted GFD-KO mice CK level
showed only a slight increase not sig-
niﬁcant. G) As expected, in fasted mice
blood glucose was lower than in fed mice.
H) Because of the high protein intake, BUN
was higher in ad libitum-fed GFD-KO mice
than in SD-KO. In fasted GFD-KO mice urea
in the bloodstream decreased respect to ad
libitum fed GFD-KO mice, on the contrary in
fasted SD-KO mice BUN increased. These
data highlight that GFD exerts a protective
role against muscle proteolysis during
fasting. The BUN/creatinine ratio decreased
in fasted GFD-KO mice respect to ad libitum
GFD-KO mice due to the stop of protein in-
take.
Except for G (n=6, 3M, 3F), fasted GFD-
KO mice: n=5 (3M, 2F) for each group;
fasted SD-KO mice: n= 4 (2M, 2F) for each
group; ad libitum fed mice: n=3 (2M, 1F)
for each group. Data are shown as mean ±
standard deviation. *P < 0.05;
**P < 0.01; ***P < 0.001.
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3.5.1. Expression proﬁling of GSDIII mice compared to WT mice
A generalized trend of over expression was noticed in glycolysis,
gluconeogenesis, glycogen synthesis and glycogen degradation path-
ways in the liver of GSDIII mice respect to the WT mice (Fig. 6B). In
contrast, Gck was signiﬁcantly downregulated (fold change 0.45,
P < 0.05). In GSDIII mice the expression of genes coding for the key
enzymes of glycolysis, Pfkl and Pklr, was respectively unchanged and
upregulated. Genes encoding for the TCA cycle did not show any sig-
niﬁcant diﬀerence in their expression compared to WT mice. Con-
versely, Pdk1, Pdk3 and Pdk4 showed an increased expression (fold
changes: Pdk1 1.87, Pdk3 2.51 (P < 0.05), Pdk4 2.76), representing a
possible inhibition on pyruvate dehydrogenase complex. The key en-
zymes of gluconeogenesis, encoded by Pcx, Pck1, Pck2 and Fbp1 genes,
were increased, respectively, 1.62 (P < 0.001), 1.78, 3.90 (P < 0.05)
and 1.63 (P < 0.001) folds, indicating a possible activation of this
pathway. The expression of G6pc, encoding for the key enzyme of
regulation of glycaemia by promoting the release of glucose in the
blood ﬂow, was similar to that of WT mice as well as for the pentose
phosphate pathway. In GSDIII mice the expression of the genes of
glycogen metabolism was similar to that of WT mice, except for Ugp2
that was upregulated 2-fold (P < 0.05) and Pygl that was slightly in-
creased (fold change 1.31, P < 0.05).
In skeletal muscle, genes coding for glycolytic enzymes showed a
trend toward a downregulation as well as genes encoding for proteins of
TCA cycle, gluconeogenesis and pentose phosphate pathway (Fig. 6E).
Moreover, since neither Pfkm nor Pkm, the muscle isoforms of phos-
phofructokinase and pyruvate kinase, are included in the array, we
chose to further analyze muscle glycolysis by measuring the enzyme
activities (Table 2), as described later. Glycogen metabolism was also
downregulated, particularly, Gys1 and Ugp2 were downregulated al-
most 2-fold (fold changes: Gys1 0.57, P < 0.01; Ugp2 0.60).
3.5.2. Expression proﬁling of GFD-KO mice compared to WT mice
The liver from GFD-KO mice showed a generalized overexpression
A D
B
Hk2 Pgam2 Pcx Acly Idh1 Suclg1 Mdh2 Gsk3a Phkb
Gck Eno3 Pck1 Pdha1 Idh2 Suclg2 G6pdx Gsk3b Phkg1
Galm Pdk1 Pck2 Pdhb Idh3a Sdha H6pd Phka1
Pgm1 Pdk2 Fbp2 Dlat Idh3b Sdhb Rpe Pygm
Gpi1 Pdk3 G6pc3 Dld Idh3g Sdhc Rpia Pgm2
Aldoa Pdk4 Ugp2 Cs Ogdh Sdhd Tkt Pgm3
Tpi1 Pdp2 Gys1 Aco1 Dlst Fh1 Taldo1 Prps1
Pgk1 Pdpr Gbe1 Aco2 Sucla2 Mdh1 Rbks Prps2
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-1,64 -1,44 -1,19 -1,32 -1,09 -1,15 1,28 -1,09 1,37
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Fig. 6. Gene expression analysis in the liver and the skeletal muscle of Agl-KO and GFD-KO mice compared to WT mice. A, D) Liver and vastus of 2-month old mice
(n=4, (2M, 2F)) were examined and the expression proﬁling of genes involved in glucose and glycogen metabolism was analyzed. B, E) Heat maps of liver (B) and
skeletal muscle (E) showed gene expression proﬁle in untreated Agl-KO mice compared to WT mice. C, F) Heat maps of liver (C) and skeletal muscle (F) showed gene
expression proﬁle in GFD-KO mice compared to WT mice. G) Color code for the diﬀerent pathways analyzed.
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of both glucose and glycogen metabolism genes respect to WT mice
(Fig. 6C). Gck was signiﬁcantly downregulated (fold change 0.45,
P < 0.05), as in untreated mice. In GFD-KO mice the expression of the
key enzymes of glycolysis, Pfkl and Pklr, was respectively unchanged
and 2-fold downregulated. The TCA cycle genes were generally upre-
gulated respect to WT mice, and a number of genes was 2-fold upre-
gulated: Aco2, Idh2, Suclg1, Fh1, Mdh1 and Mdh2 (all P < 0.01). The
Pdk2, Pdk3 and Pdk4 showed an increased expression respect to WT
mice (fold changes: Pdk2 1.61 (P < 0.01); Pdk3 1.78; Pdk4 1.68), but
lower than that observed in SD-KO mice. The key enzymes of gluco-
neogenesis Pcx, Pck1, Pck2 and Fbp1 genes were increased 1.33
(P < 0.05), 2.53, 2.63 (P < 0.01) and 2.86 (P < 0.001) fold, re-
spectively, indicating again an activation of the gluconeogenesis
pathway that in these mice was sustained by the dietary amino acids. As
seen in untreated GSDIII mice, in GFD-KO animals the expression of
glycogen metabolism genes did not show diﬀerences compared to WT
mice.
Skeletal muscle gene expression showed few diﬀerences between
GFD-KO and WT mice (Fig. 6F). Hk2 was downregulated (P < 0.05)
while genes involved in glycolysis were generally downregulated.
Again, the activities of glycolysis enzymes were analyzed (Table 2) as
described in the next paragraph. Genes involved in TCA cycle, gluco-
neogenesis and pentose phosphate pathway did not show major dif-
ferences compared to WT mice. Gys1 was slightly downregulated
(P < 0.05).
3.6. Glycogen phosphorylase, glycolysis and respiratory chain activities in
liver and skeletal muscle
Liver glycogen phosphorylase activity was 3-fold more active in 2-
month old GSDIII mice than in WT mice (P < 0.001), while, in GFD-KO
and HPD-KO mice, it was decreased respect to untreated mice, but
higher than WT mice (Table 2).
Glycolytic enzyme activities in the liver from SD-KO mice were in-
creased if compared to WT mice with the exception of phospho-
fructokinase, that was unchanged, and of pyruvate kinase, that was
reduced by 35% (P < 0.05). Liver pyruvate kinase activity decreased,
respectively, by 71.4% (P < 0.05) and 78.6% (P < 0.01) in GFD-KO
and HPD-KO mice compared to WT mice, while phosphofructokinase
activity decreased by 35% (P < 0.05) only in mice treated with GFD.
In both HPD- and GFD-treated mice, the activities of the other glyco-
lytic enzymes were increased when compared to WT, but were reduced
when compared to untreated mice (Table 2).
Enzyme activities increased in gastrocnemius from 2-month old SD-
KO mice compared to WT mice (Table 2). In particular, the phospho-
fructokinase increased by 130% (P < 0.01), whereas pyruvate kinase
showed a slight increase (SD-KO 3.94 ± 0.18 vs. WT
3.35 ± 0.07 μmol/min/mg protein, P < 0.001). In GFD-KO mice,
phosphofructokinase activity was increased by 86% (P < 0.01),
whereas pyruvate kinase was 23% more active (P < 0.01) compared to
WT mice. In SD-KO mice the other glycolytic activities increased
compared to WT mice and resulted unchanged or slightly increased in
GFD-KO mice.
The activities of respiratory chain enzymes were analyzed in gas-
trocnemius of 2-month old WT, SD-KO and GFD-KO mice (Suppl.
Table 1). We found diﬀerences only in the activity of complex II that
was slightly reduced in untreated mice compared to WT mice
(P < 0.05). Complex II activity increased in GFD-KO mice up to reach
the activity of WT mice.
4. Discussion
In this study we explored the long-term administration of two kinds
of high-protein/low-carbohydrate diet to the GSDIII mouse model. The
main ﬁnding of the present study is that a glucose-free diet, containing
a very limited amount of carbohydrate (< 0.5% of starch and sugar)
and a high-protein content (53.4%), improves the exercise tolerance of
GSDIII mice (Fig. 2C) and reduces hepatomegaly by about 20%
(Fig. 1B).
We demonstrated that cardiac and skeletal muscle glycogen storage
may be limited by nutritional management without drop in blood
glucose (Figs. 1C; 2A, B; Suppl. Fig. 4 F). GFD-KO mice showed great
improvement of exercise tolerance allowing them to run up to
10months versus 5months of age as for the untreated and HPD-treated
mice (Fig. 2C). Histological ﬁndings showed a dramatic decrease of
vacuolization in the vastus, gastrocnemius and diaphragm of GFD-
treated mice up to 9months of age (Fig. 4). Taken together, these data
suggest a protective action of dietary proteins against skeletal muscle
degeneration.
A recent study about proteomics of mouse skeletal muscle quanti-
ﬁed contractile proteins as 53.6% of total protein mass and proteins of
core metabolic pathways as 10% of total protein mass [21]. After two
months of GFD administration, the protein content in skeletal muscle in
treated mice was signiﬁcantly augmented (data not shown). It can be
speculated that in these mice the protein increase also has led to an
increment of contractile proteins.
Furthermore, when fasted, SD-KO mice manifested important dif-
ferences respect to GFD-KO, suggesting a better metabolic control
Table 2
Activity analysis of glycolytic enzymes in liver and skeletal muscle from 2-month old WT, SD-KO and treated KO mice.
Enzyme Liver Skeletal muscle (gastrocnemius)
WT mice SD-KO mice GFD-KO mice HPD-KO mice WT mice SD-KO mice GFD-KO mice
Activity μmol/min/mg protein
Glycogen phosphorylase 0.045 ± 0.007 0.127 ± 0.015*** 0.070 ± 0.015** 0.073 ± 0.004*** n.d. n.d. n.d.
Phosphoglucomutase 0.11 ± 0.01 0.16 ± 0.01*** 0.12 ± 0.01§§ 0.14 ± 0.01**,§ 0.34 ± 0.04 0.34 ± 0.05 0.38 ± 0.03
Glucose-6-phosphate isomerase 0.88 ± 0.18 1.97 ± 0.30*** 1.08 ± 0.09§§§ 1.08 ± 0.02*,§§§ 2.84 ± 0.20 3.52 ± 0.07*** 3.73 ± 0.24**
Phosphofructokinase 0.017 ± 0.002 0.019 ± 0.003 0.011 ± 0.002*,§§ 0.019 ± 0.005 0.66 ± 0.19 1.52 ± 0.32** 1.23 ± 0.08**
Aldolase 0.05 ± 0.01 0.12 ± 0.01*** 0.08 ± 0.01**,§§§ 0.08 ± 0.01**,§§ 1.35 ± 0.12 1.54 ± 0.23 1.51 ± 0.14
Glyceraldehyde-3-phosphate
dehydrogenase
0.94 ± 0.33 0.87 ± 0.48 1.03 ± 0.22 1.52 ± 0.07*,§ 4.29 ± 0.44 5.08 ± 0.24* 5.17 ± 1.42
Phosphoglycerate kinase 1.41 ± 0.12 2.10 ± 0.07*** 1.60 ± 0.15§§ 3.20 ± 0.14* 2.23 ± 0.14 2.59 ± 0.10** 2.63 ± 0.43
Phosphoglycerate mutase 0.60 ± 0.03 0.94 ± 0.07*** 0.85 ± 0.06*** 0.92 ± 0.02*** 7.18 ± 0.43 7.65 ± 0.55 8.56 ± 0.65*
Enolase 0.44 ± 0.09 0.79 ± 0.14*** 0.58 ± 0.07*,§ 0.51 ± 0.01§§ 2.66 ± 0.15 2.90 ± 0.25 2.97 ± 0.25
Pyruvate kinase 0.14 ± 0.05 0.09 ± 0.02* 0.04 ± 0.01*,§§ 0.03 ± 0.00**,§§ 3.35 ± 0.07 3.94 ± 0.18*** 4.14 ± 0.30**
Lactate dehydrogenase 1.60 ± 0.15 1.77 ± 0.34 1.57 ± 0.15 1.22 ± 0.09**,§ 4.15 ± 0.28 4.46 ± 0.21 4.86 ± 0.38*
The enzymes shared by glycolysis and gluconeogenesis are in bold. Data are shown as mean ± standard deviation. Liver: WT and SD-KO mice n= 6 (3M, 3F); GFD-
KO mice n=4 (2M, 2F); HPD-KO mice n= 3 (2M, 1F). Skeletal muscle (gastrocnemius): n=4 for each group (2M, 2F). * p < 0.05, ** p < 0.01, *** p < 0.001
vs. WT mice; § p < 0.05, §§ p < 0.01, §§§ p < 0.001 vs. SD-KO mice. n.d.: not determined.
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during fasting and, again, a protective role against muscle proteolysis in
the latter group (Fig. 5). In fact, SD-KO mice presented increased BUN
during fasting, likely due to the catabolism of muscle tissue in the ab-
sence of active glycogenolysis. In addition, the long-term administra-
tion of GFD did not worsen the serum parameters even after eight
months of diet (Suppl. Fig. 4).
Administration of HPD, which is a high-protein (45.9%)/low-car-
bohydrate (27.5%) diet, slightly improved the muscle performance
(Fig. 2C) and reduced the vacuolization in vastus and gastrocnemius
(Fig. 4). However, muscle function decreased and, at 5months of age,
HPD-treated mice were indistinguishable from the untreated. This has
led us to hypothesize that the protein increase induced by HPD was
suﬃcient to provide more energy to sustain exercise but not to protect
the liver and muscle from long-term glycogen storage and the disrup-
tion of the contraction machinery. In contrast, GFD diet has brought
two main beneﬁts: ﬁrst, a decrease in glycogen buildup and vacuoli-
zation of skeletal muscle ﬁbers; second, providing suﬃcient fuel to
sustain exercise through gluconeogenesis. As recently described, GSDIII
patients suﬀer from energy deﬁciency during exercise caused by im-
paired glycogenolysis [22].
To deﬁne the metabolic changes induced by the GFD we analyzed
the expression of genes involved in glycogen and glucose metabolism in
the liver and skeletal muscle (Fig. 6). In most cases, the upregulation (in
the liver) or the downregulation (in the skeletal muscle) observed did
not reach the standard cut-oﬀ used in gene expression analysis (2-fold),
but were seemingly suﬃcient to show a tendency for gene expression in
each tissue. The major problems of our expression analysis, especially
in skeletal muscle, were the low number of samples and their high
variability which produced low statistical signiﬁcance. However, this
analysis is an important step to understand the diﬀerences between
healthy and diseased tissues, and between treated and untreated tis-
sues.
Glucose and glycogen metabolism are fundamental for cell life and
involve many important pathways that are tightly regulated in diﬀerent
ways (expression, allosteric, hormonal regulation), likely accounting
for the diﬀerences detected between gene expression and enzyme ac-
tivities. Glycolysis and gluconeogenesis share seven enzymes, whose
activities were increased in GSDIII mice (Table 2). Hexokinase, phos-
phofructokinase and pyruvate kinase control the glucose inﬂux into
glycolysis. Considering the reduced activity of pyruvate kinase, the
increase of these enzyme activities should be due to the activation of
gluconeogenesis to provide glucose to the whole organism. This hy-
pothesis is also supported by the increased expression of the regulatory
genes of gluconeogenesis in the liver (Pcx, Pck1, Pck2, Fbp1).
The upregulation of gluconeogenesis and the inhibition of glycolysis
in the liver conﬁrm the current working hypothesis. The increased in-
take of proteins from GFD, together with null supply of glucose, acts
inhibiting the glycolytic pathway, activating gluconeogenesis, and de-
creasing the use of glucose in favor of amino acid use. Dietary proteins
are also carried in the TCA cycle to produce energy and substrates
needed by the cell, bypassing the inhibition of glycolysis. The 47%
reduction of liver glycogen phosphorylase activity in GFD-KO respect to
SD-KO mice supports this hypothesis. The increased activation of gly-
colytic enzymes in GSDIII skeletal muscle, primarily phospho-
fructokinase and pyruvate kinase, indicated that this tissue needs me-
tabolic energy because of impaired glycogenolysis. Conversely, in GFD-
KO mice skeletal muscle metabolism was sustained by the high-protein
intake and by the glucose produced by the liver, therefore phospho-
fructokinase activity reduced by 20% compared to untreated mice.
The long-term intake of high-protein/low-carbohydrate diets has
been associated with increased mortality in humans, likely related to an
increased cardiovascular risk [23–25], although another study ruled
out the hypothesis that low-carbohydrate/high protein and fat diets are
associated with coronary heart disease [26]. The median survival time
of both HPD- and GFD-treated mice was lower than in untreated mice
(Suppl. Fig. 1B). This could be due to increased load on kidneys or to
increased cardiovascular risk, as in humans. Remarkably, our study
highlights that the median survival mainly decreased in the group
treated with HPD, the less extreme diet, meaning that the problem does
not seem to be related only with the protein load itself.
Today, a number of the genetic and biochemical diﬀerences (i.e.
epigenetic regulation, biosynthetic reactions, and signal transduction)
between humans and rodents are still unexplored; therefore, any
comparison must be carefully handled. On the other hand, studying a
rare disease such as GSDIII is complicated, indeed only dietary treat-
ments aiming to improve cardiac signs have been trialled, and aﬀected
subjects were followed for some months or few years. Our ﬁndings
demonstrate that it is possible to limit glycogen deposition and skeletal
muscle degeneration acting on nutrition by drastically limiting carbo-
hydrates and increasing proteins. In these conditions, blood glucose did
not drop down indicating that it is possible to limit glucose adminis-
tration in GSDIII.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bbadis.2018.07.031.
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